Press2022-12-28T15:23:07-05:00

Press Releases

3105, 2024

Bexion Pharmaceuticals, Inc. toPresent at BIO InternationalConvention 2024

COVINGTON, Ky., May 31, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced that the Company will present at the 2024 Biotechnology Innovation Organization (BIO) International Convention taking place June 3-6, 2024, in San Diego, California. Presentation Details: Location: Theater 1, Hall A, [...]

1004, 2024

Bexion Pharmaceuticals, Inc. Announces Poster Presentation on BXQ-350 at the American Association for Cancer Research (AACR) Annual Meeting 2024

COVINGTON, Ky., April 10, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company presented a poster on BXQ-350 during the American Association for Cancer Research (AACR) Annual Meeting 2024 which took place April 5-10, 2024, in San Diego, CA. Poster details are included below. [...]

2802, 2024

Bexion Pharmaceuticals, Inc. Appoints Dr. Tariq Arshad as Chief Medical Officer

COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical- stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer. Dr. Arshad is an oncologist with more than 25 years of experience and a successful track record of [...]

1601, 2024

Bexion Pharmaceuticals, Inc. Announces Poster Presentation at ASCO GI 2024

COVINGTON, Ky., Jan. 16, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced a Trials in Progress poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 18-20, 2024, in San Francisco, CA. Poster details are included below. Poster Details: Session [...]

501, 2024

Bexion Pharmaceuticals, Inc. to Present at Biotech Showcase 2024

Company now enrolling a Phase 1b/2 study in 1st Line mCRC and a PK/PD study in CIPN COVINGTON, Ky., January 5, 2024 /PRNewswire/ — Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will present at Biotech Showcase 2024 during the J.P. Morgan [...]

1210, 2023

Bexion Pharmaceuticals, Inc. to Participate in the 3rd Annual Needham Private Biotech Company Virtual 1×1 Forum

COVINGTON, Ky., Oct. 12, 2023 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum. The conference will be held virtually, from October 17-18, 2023. Scott Shively, CEO and [...]

Go to Top